Evidence map›Paper›PMID 39844410›Full record

ReviewCurrent cancer drug targets2026

Targeting Glutamine Metabolic Reprogramming in Pancreatic Cancer: Current Insights and Future Directions.

Yanhui Ma, Mingling Wang, Kexin Zhang, Fangbing Ren, Yuqun Wang, Wenqiang Zhang, Chengxia Kan, Fang Han, Hongxi Sun, Xiaodong Sun

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cancer drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yanhui MaDepartment of Endocrinology and Metabolism, Affiliated Hospital of Shandong Second Medical University, Weifang 261031, Shandong Province, China.
Mingling WangShandong Provincial Medicine and Health Key Laboratory of Clinical Anesthesia, School of Anesthesiology, Shandong Second Medical University, Weifang, 261053, Shandong Province, China.
Kexin ZhangDepartment of Endocrinology and Metabolism, Affiliated Hospital of Shandong Second Medical University, Weifang 261031, Shandong Province, China.
Fangbing RenDepartment of Pathology, Affiliated Hospital of Shandong Second Medical University, Weifang 261031, Shandong Province, China.
Yuqun WangDepartment of Endocrinology and Metabolism, Affiliated Hospital of Shandong Second Medical University, Weifang 261031, Shandong Province, China.
Wenqiang ZhangDepartment of Pathology, Affiliated Hospital of Shandong Second Medical University, Weifang 261031, Shandong Province, China.
Chengxia KanDepartment of Endocrinology and Metabolism, Affiliated Hospital of Shandong Second Medical University, Weifang 261031, Shandong Province, China.
Fang HanDepartment of Endocrinology and Metabolism, Affiliated Hospital of Shandong Second Medical University, Weifang 261031, Shandong Province, China.
Hongxi SunDepartment of Endocrinology and Metabolism, Affiliated Hospital of Shandong Second Medical University, Weifang 261031, Shandong Province, China.
Xiaodong SunDepartment of Endocrinology and Metabolism, Affiliated Hospital of Shandong Second Medical University, Weifang 261031, Shandong Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic Cancer (PC) is a devastating malignancy with a poor prognosis and increasing morbidity. Current treatment strategies have limited efficacy in improving patient survival. Metabolic reprogramming is a hallmark of cancer and plays a key role in the progression and maintenance of PC. PC cells exhibit a unique glutamine metabolism that is distinct from other cancer types. The non-classical pathway of glutamine metabolic reprogramming plays a "permissive role" in the survival and proliferation of PC cells, mainly by affecting the redox homeostasis of the cells. In this review, we compare and contrast the canonical and non-canonical glutamine metabolic pathways and highlight recent advances in targeting non-canonical glutamine metabolism for therapeutic intervention. This may provide novel insights and opportunities for exploiting glutamine metabolic reprogramming in PC treatment.

Indexed as

Antineoplastic AgentsGlutaminePancreatic NeoplasmsAnimalsHumansMetabolic ReprogrammingMolecular Targeted TherapyAntineoplastic AgentsGlutamineglutamine metabolismglutamine metabolism inhibitorsmetabolic reprogrammingPancreatic cancertargeted treatment.

Identifiers

PMID39844410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.